HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s share price rose 3% during mid-day trading on Friday . The company traded as high as $3.09 and last traded at $3.09. Approximately 100 shares changed hands during trading, a decline of 87% from the average daily volume of 784 shares. The stock had previously closed at $3.00.
HLS Therapeutics Stock Up 3.0%
The firm has a fifty day moving average price of $3.21 and a 200 day moving average price of $3.28.
HLS Therapeutics Company Profile
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Further Reading
- Five stocks we like better than HLS Therapeutics
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
